Actionable Mutation Profile of Sun-Protected Melanomas in South America

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
CAMILLO, Claudia M. C.
OLIVEIRA, Katia K.
CARRARO, Dirce M.
SANGUEZA, Martin
Citação
AMERICAN JOURNAL OF DERMATOPATHOLOGY, v.44, n.10, p.741-747, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Melanomas that arise in sun-protected sites, including acral and oral mucosal melanomas, are likely under the control of unique, specific mechanisms that lead to mutagenesis through various pathways. In this study, we examined somatic mutations in tumors by targeted sequencing using a custom Ion Ampliseq Panel, comprising hotspots of 14 genes that are frequently mutated in solid tumors. Tumor DNA was extracted from 9 formalin fixation, paraffin-embedded sun-protected melanomas (4 primary oral mucosal melanomas and 5 acral lentiginous melanomas), and we identified mutations in the NRAS, PIK3CA, EGFR, HRAS, ERBB2, and ROSI genes. This study reveals new actionable mutations that are potential targets in the treatment of photo-protected melanomas. Additional studies on more of these melanoma subtypes could confirm our findings and identify new mutations.
Palavras-chave
acral lentiginous melanoma, primary oral mucosal melanoma, mutation, sun-protected, next-generation sequencing
URI
https://observatorio.fm.usp.br/handle/OPI/49187
Referências
  1. Aguas SC, 2009, MED ORAL PATOL ORAL, V14, pE265
  2. Akslen LA, 2008, MELANOMA RES, V18, P29, DOI 10.1097/CMR.0b013e3282f32517
  3. [Anonymous], 2020, COSMIC CATALOGUE SOM
  4. Berra CM, 2019, APPL CANC RES, V39, P1, DOI 10.1186/s41241-019-0075-2
  5. Boone B, 2011, J CUTAN PATHOL, V38, P492, DOI 10.1111/j.1600-0560.2011.01673.x
  6. Borkowska Aneta, 2020, Oncotarget, V11, P2404, DOI 10.18632/oncotarget.27642
  7. Bustos BD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00606-w
  8. Couts KL, 2018, MOL CANCER THER, V17, P222, DOI 10.1158/1535-7163.MCT-17-0472
  9. Davies KD, 2013, CLIN CANCER RES, V19, P4040, DOI 10.1158/1078-0432.CCR-12-2851
  10. de Biase D, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040250
  11. Desai A, 2017, CLIN EXP DERMATOL, V42, P845, DOI 10.1111/ced.13243
  12. Dietel M, 2015, CANCER GENE THER, V22, P417, DOI 10.1038/cgt.2015.39
  13. Dika E, 2020, AM J CLIN PATHOL, V153, P664, DOI 10.1093/ajcp/aqz209
  14. El-Deeb IM, 2011, MED RES REV, V31, P794, DOI 10.1002/med.20206
  15. Garzino-Demo P, 2004, J CRANIO MAXILL SURG, V32, P251, DOI 10.1016/j.jcms.2003.12.007
  16. Goswami RS, 2015, CLIN CANCER RES, V21, P2644, DOI 10.1158/1078-0432.CCR-14-2391
  17. Gottesdiener LS, 2018, CLIN CANCER RES, V24, P5815, DOI 10.1158/1078-0432.CCR-18-1397
  18. Haugh AM, 2018, J INVEST DERMATOL, V138, P384, DOI 10.1016/j.jid.2017.08.022
  19. Hsieh R, 2017, AM J DERMATOPATH, V39, P104, DOI 10.1097/DAD.0000000000000605
  20. Hsieh R, 2013, AM J DERMATOPATH, V35, P167, DOI 10.1097/DAD.0b013e31825fa1f6
  21. Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769
  22. Kosmidou V, 2014, HUM MUTAT, V35, P329, DOI 10.1002/humu.22496
  23. Kuchelmeister C, 2000, BRIT J DERMATOL, V143, P275, DOI 10.1046/j.1365-2133.2000.03651.x
  24. Lee SH, 2016, CANCER RES TREAT, V48, P853, DOI 10.4143/crt.2014.356
  25. Lourenco SV, 2009, AM J DERMATOPATH, V31, P323, DOI 10.1097/DAD.0b013e3181a0d37c
  26. Lv JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31432
  27. Manca A, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0401-8
  28. Merkel EA, 2017, LAB INVEST, V97, P630, DOI 10.1038/labinvest.2016.147
  29. Mikkelsen LH, 2016, APMIS, V124, P475, DOI 10.1111/apm.12529
  30. Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349
  31. Olbryt M, 2020, TARGET ONCOL, V15, P101, DOI 10.1007/s11523-020-00695-0
  32. Omholt K, 2006, MELANOMA RES, V16, P197, DOI 10.1097/01.cmr.0000200488.77970.e3
  33. Rakosy Z, 2007, INT J CANCER, V121, P1729, DOI 10.1002/ijc.22928
  34. Schaefer T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005753
  35. Serrati S, 2016, ONCOTARGETS THER, V9, P7355, DOI 10.2147/OTT.S99807
  36. Shayanfar Nasrin, 2015, Asian Pac J Cancer Prev, V16, P421
  37. Shi Katherine, 2019, J Am Acad Dermatol, DOI 10.1016/j.jaad.2019.07.017
  38. Shim JH, 2017, EXP DERMATOL, V26, P883, DOI 10.1111/exd.13321
  39. Silva JM, 2017, PIGM CELL MELANOMA R, V30, P353, DOI 10.1111/pcmr.12586
  40. Sini MC, 2018, ONCOTARGET, V9, P8531, DOI 10.18632/ONCOTARGET.23989
  41. Sortino-Rachou AM, 2009, ORAL ONCOL, V45, P254, DOI 10.1016/j.oraloncology.2008.04.015
  42. Tamirat MZ, 2020, J VIS EXP, V2020, P1
  43. Thomas NE, 2015, JAMA ONCOL, V1, P359, DOI 10.1001/jamaoncol.2015.0493
  44. Turner J, 2017, PIGM CELL MELANOMA R, V30, P53, DOI 10.1111/pcmr.12560
  45. Uguen A, 2016, FUTURE ONCOL, V12, P1911, DOI 10.2217/fon-2016-0050
  46. Ulivieri Alessandra, 2015, Oncotarget, V6, P19868
  47. Wei XT, 2020, ANN SURG ONCOL, V27, P3478, DOI 10.1245/s10434-020-08418-5
  48. Whitwam T, 2007, ONCOGENE, V26, P4563, DOI 10.1038/sj.onc.1210239
  49. Xu YC, 2020, J COMPUT BIOL, V27, P9, DOI 10.1089/cmb.2019.0197
  50. Zaremba A, 2019, EUR J CANCER, V119, P66, DOI 10.1016/j.ejca.2019.07.008
  51. Zebary A, 2013, J DERMATOL SCI, V72, P284, DOI 10.1016/j.jdermsci.2013.07.013

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - ODS/03